Ana Sayfa | Dergi Hakkında | Yayın Kurulu | Telif Hakkı Devir Formu | Arşiv | Yayın Arama | Yazarlara Bilgi | Etik Politikalar | İletişim  
2021, Cilt 51, Sayı 4, Sayfa(lar) 326-333
[ Türkçe Özet ] [ PDF ] [ Benzer Makaleler ]
Hope in the Treatment of Candida Vaginitis: Ibrexafungerp
Ayşe Sultan Karakoyun, Macit İlkit
Çukurova Üniversitesi Tıp Fakültesi, Mikrobiyoloji Anabilim Dalı, Mikoloji Bilim Dalı, Adana, Türkiye
Keywords: Antifungal agents, aspergillosis, candidiasis, fungal cell wall, fungerp

Candida vaginitis (CV) is a neglected but growing public health problem. It is estimated that three out of four women have had at least one CV attack. The diagnosis and treatment of CV is often inadequate due to the tendency of women to self-diagnose and use over-the-counter drugs when they have vaginal or vulvar complaints, and clinicians plan treatment only according to clinical findings. There are limitations regarding the safety and efficacy of oral azoles, which are primarily preferred for the treatment of vaginitis, and these drugs have not revealed the desired levels of clinical or mycological cure. Also, there are a few options for current drugs used for treatment are not numerous the development of new antifungal drugs is thus urgently needed. Ibrexafungerp (IBX) is a semisynthetic triterpenoid glucan synthase inhibitor derived from enfumafungin. IBX has been shown to be a promising oral antifungal in the treatment of acute CV, and its use was approved on June 1, 2021. IBX is remarkable by it’s high oral bioavailability, low risk of side effects, few drug-drug interactions, good tissue penetration, increased activity at low pH in the vagina, and efficacy with regard to multi-drug-resistant fungi. In this review, in vitro and in vivo data on IBX were evaluated and compiled in light of current knowledge.

[ Türkçe Özet ] [ PDF ] [ Benzer Makaleler ]
Ana Sayfa | Dergi Hakkında | Yayın Kurulu | Telif Hakkı Devir Formu | Arşiv | Yayın Arama | Yazarlara Bilgi | Etik Politikalar | İletişim